Central to inflammatory bowel disease (IBD) pathogenesis is loss of mucosal barrier function. Emerging evidence implicates extracellular adenosine signaling in attenuating mucosal inflammation. We hypothesized that adenosinemediated protection from intestinal barrier dysfunction involves tissue-specific signaling through the A2B adenosine receptor (Adora2b) at the intestinal mucosal surface. To address this hypothesis, we combined pharmacologic studies and studies in mice with global or tissue-specific deletion of the Adora2b receptor. 
INTRODUCTION
Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) are relapsing-remitting conditions characterized by uncontrolled intestinal inflammation and tissue destruction. 1 A recent study points to the increasing incidence and prevalence of both CD and UC in North America, highlighting the urgent need for effective therapeutic options. 2 Genome-wide association studies have established a firm link between dysfunction in host-microbial responses and aberrant mucosal barrier protection with the development of IBD. 1 As such, greater understanding of dysregulated mucosal homeostasis in IBD may provide novel therapeutic options. Release of extracellular adenosine was previously implicated as an endogenous protective response during mucosal inflammation (reviewed in Aherne et al. ). Adenosine acts through a number of cell surface receptors to mediate its signaling responses. 3 Studies to date have outlined a role for the A2A (A2A adenosine receptor (Adora2a)) [4] [5] [6] [7] and A2B (Adora2b) [8] [9] [10] [11] [12] [13] adenosine receptors in acute inflammation. However, the functional consequences of adenosine release and signaling during mucosal inflammation observed in IBD remains to be defined. Previous observations indicate that generation of extracellular adenosine in models of IBD is profoundly protective. [14] [15] [16] Adenosine signaling through Adora2a protects the intestinal mucosa in a chronic model of IBD; 17 however, the role of the Adora2b receptor remains undefined. Recent findings highlight a tissue-protective role for Adora2b signaling during acute intestinal inflammation as occurs in IBD. 12, 18 These studies suggest that Adora2b expression at the intestinal epithelium is a key protective signaling pathway during acute inflammation. However, in separate studies, intestinal epithelial Adora2b signaling was observed to be deleterious in models of IBD. [19] [20] [21] Reasons for these divergent findings have yet to elucidated, but may be due in part to genetic background differences in mice studied or in experimental design. We postulated that Adora2b functions in a tissue-specific manner at the mucosal surface to mediate protection in intestinal inflammation. Our aim was to investigate the function of Adora2b signaling at the mucosal surface during acute intestinal inflammation as experienced during IBD. To examine this, we generated novel mouse lines with tissue-specific deletion of the Adora2b receptor. Our studies demonstrated that mice with global knockout of Adora2b (Adora2b À / À ) experience rapid, early onset of acute DSS (dextran sulfate sodium) colitis associated with premature loss of mucosal barrier function. Tissue-specific murine studies established a definitive role for intestinal epithelial Adora2b expression in driving mucosal protection during acute colitis. Supported by in vitro findings with Adora2b intestinal epithelial knockdown (KD) cells, we have outlined the Adora2b signaling pathway as a directly protective mechanism in repairing the damaged mucosal barrier through phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in the intestinal epithelium.
Taken together, we observed that tissue-specific expression of the Adora2b receptor on the intestinal epithelium is an endogenous protective response to maintain mucosal barrier function during acute colitis. Pharmacological studies demonstrate that targeting the Adora2b receptor mediates mucosal protection from acute intestinal inflammation. This points to the exciting possibility of exploiting Adora2b signaling in a tissue-specific manner as a therapeutic approach in IBD.
RESULTS

Mice deficient in Adora2b demonstrate early onset and increased severity of DSS colitis
The exact role of the Adora2b receptor in IBD remains to be defined. In previous studies, Adora2b signaling on the intestinal epithelium was implicated as the relevant signaling pathway. 12, [19] [20] [21] However, these studies do not agree on whether Adora2b has a beneficial or deleterious role in models of IBD. We hypothesized that previous divergent findings may be due to distinct roles for Adora2b on different stromal tissue. To investigate this, we assessed mice with whole-body deletion of Adora2b (Adora2b À / À ) over the course of DSS colitis.
Decreased survival of Adora2b
À / À mice compared with wildtype controls (Adora2b þ / þ ) was noted when studies were performed using 4.5% DSS (Supplementary Figure S1 online).
Owing to high mortality rates in Adora2b À / À mice at this percentage, we performed subsequent studies with 3-3.5% DSS. Monitoring mice during the course of acute colitis revealed increased weight loss in Adora2b À / À mice compared with wild-type controls ( Figure 1a) . Adora2b À / À mice exhibited significantly greater colonic shortening ( Figure 1b) and loss of epithelial barrier function (Figure 1c) , as measured by FITC (fluorescein isothiocyanate)-dextran permeability, compared with controls, from as early as day 3 following DSS. Upon termination of the study, Adora2b
À / À mice demonstrated enhanced neutrophil numbers in the colon (Figure 1d ) and dramatically increased severity of histological disease (Figure 1e, f) . These findings indicate that deficiency of Adora2b results in earlier onset of tissue damage and loss of mucosal barrier function during DSS.
Vascular endothelial expression of Adora2b does not have a role in acute colitis
Drawing from our findings in Adora2b À / À mice ( Figure 1 ), we investigated a tissue-specific role for stromal expression of the Adora2b receptor using newly developed tissue-specific knockout mice. A previous study implicated vascular endothelial Adora2b as a key regulator of acute inflammation. 8 Mice with deletion of Adora2b in vascular endothelial cells (Adora2b
VeCadCre þ ) and their wild-type controls (VeCadCre þ ) were exposed to DSS. Genotyping PCR of tails (not shown) and whole colonic tissues (Supplementary Figure S2b) demonstrated Cre and Flox expression in desired tissue. Deletion of Adora2b in the vascular endothelium had no effect on acute inflammation experienced during DSS, as evidenced by no differences in weight loss, colon length, and histological damage between Adora2b fl/fl VeCadCre þ and VeCadCre þ mice (Figure 2a-d) . These findings indicate that Adora2b expression on the vascular endothelium has no significant role in acute intestinal inflammation as observed in IBD.
Specific deletion of intestinal epithelial Adora2b results in increased severity of acute colitis
Having observed no significant impact of vascular endothelialderived Adora2b on the outcome of DSS colitis, we investigated the function of intestinal epithelial-expressed Adora2b during acute colitis. Previous findings indicate that Adora2b is expressed to a high level on intestinal epithelial cells and its expression is induced during colonic inflammation. 22 We generated mice with deletion of Adora2b in intestinal epithelial cells (Adora2b fl/fl VillinCre þ ) and exposed them along with wild-type controls (VillinCre þ ) to DSS. Genotyping PCR of tails (not shown) and colonic intestinal epithelial cells (described in Flow Cytometry methods: Supplementary Figure S2c following DSS compared with VillinCre þ controls (Figure 3b , c, respectively). Tissue cytokine analysis revealed a trend towards an increase in cytokine levels in the tissue of Adora2b fl/fl VillinCre þ mice compared with controls, particularly in interleukin-6 (IL-6) ( Figure 3d) . Finally, histological analysis of the distal colon (Figure 3e , f) demonstrated that Adora2b fl/fl VillinCre þ mice experienced a significantly worse outcome of DSS colitis compared with wild-type controls. Our observations highlight a tissue-specific role for expression of Adora2b on intestinal epithelial cells as a protective response during the acute phase of intestinal inflammation.
An Adora2b-specific agonist is protective during acute colitis Our studies reveal that endogenous expression of Adora2b on the intestinal epithelium is a protective mechanism during acute mucosal inflammation. However, the effect of an exogenous Adora2b agonist during acute colitis has not been investigated. We undertook studies using a specific Adora2b agonist (BAY 60-6583). This agonist has previously been demonstrated to have a high degree of specificity for the Adora2b receptor. 23, 24 We confirmed its ability to induce the second messenger cAMP, a known downstream signaling molecule of the Adora2b receptor in both CHO (Chinese hamster ovarian) cells expressing the human Adora2b receptor and T84 intestinal epithelial cells (Supplementary Figure S4) . Continuous administration of the Adora2b agonist provided potent tissue protection as measured by weight loss, colonic shortening, tissue permeability, tissue cytokine levels, and histological damage of the distal colon in acute DSS colitis compared with vehicle-treated controls (Figure 4a-f, respectively) . This provides the first evidence À / À or Adora2b þ / þ mice harvested following 7 days DSS. Bar ¼ 100 mm; images acquired at original magnification Â 10. (f) Blinded histological analysis of whole colon from each group following DSS. Data represent 8-10 mice per group. Unless stated otherwise, results are representative of two independent experiments with 3-10 mice per group and are displayed as mean±s.e.m. Two-way analysis of variance (ANOVA) with post hoc Bonferroni t-test was used to determine statistical weight change, but in all other cases Student's t-test was used. *Po0.5; **Po0.001; ***Po0.0001.
that an Adora2b agonist can provide mucosal protection in a model of IBD.
Adora2b signaling does not effect epithelial barrier breakdown
To date, we observed premature onset of acute colonic inflammation in mice deficient in the Adora2b receptor during DSS colitis (Figure 1) . Tissue-specific deletion identified Adora2b expression on the intestinal epithelium as the key protective signaling pathway in this model ( Figure 3) . Considering that intestinal barrier permeability was significantly enhanced early in the course of DSS in both Adora2b Figure 1c) and Adora2b fl/fl VillinCre þ mice (Figure 3c) , we sought to determine how intestinal epithelial Adora2b might modulate epithelial barrier breakdown.
A number of intrinsic and extrinsic mechanisms have been identified that regulate epithelial barrier breakdown during acute colitis. These include cytokine-induced epithelial barrier dysfunction, 25 alterations in the phosphorylation status of myosin light chain (MLC), 26 nuclear factor-kB (NF-kB) activity, 27 intestinal epithelial cell apoptosis, 28 and mucin-2 expression. 29 First, we analyzed the effect of Adora2b signaling on cytokine-induced epithelial barrier breakdown (Figure 5a ). Barrier studies were performed in T84 intestinal epithelial cells as they express high levels of the Adora2b receptor 22 in comparison with other epithelial cell lines that have been used to study Adora2b receptor function (Supplementary Figure S5a) .
30 T84 intestinal epithelial monolayers were cotreated with the Adora2b agonist or vehicle and a mixture of tumor necrosis factor-a (TNFa), IL-1b, and interferon g (IFNg) (''cytomix''). Following 72 h of treatment, a FITC-flux assay was performed to determine the flux rate across the barrier and thereby the permeability of the monolayer. Adora2b agonist treatment did not suppress the cytokine-induced increase in barrier permeability (Figure 5a) .
The phosphorylation status of MLC has been demonstrated to be intimately involved in epithelial tight junction paracellular permeability, 31 with a recent study highlighting a key role for MLC phosphorylation in intestinal permeability in IBD. 26 Treatment of polarized T84 intestinal epithelial monolayers for The master transcription factor NF-kB has a controversial role in regulating intestinal epithelial barrier function in acute colitis. 27 Studies suggest that adenosine signaling through the Adora2b receptor inhibits NF-kB transcriptional activity. 24, 30, 32 In line with previous findings, 33 we observed no effect of cotreatment with the Adora2b agonist on TNFa- (Figure 5c ) or IL-1b-(not shown) induced NF-kB transcriptional activity in intestinal epithelial cells using an NF-kB-driven luciferase reporter.
Increased epithelial cell apoptosis may result in loss of epithelial barrier function during DSS colitis. 28, 34 TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) staining revealed no differences in the number of apoptotic epithelial cells in the colon of Adora2b fl/fl VillinCre þ mice compared with VillinCre þ controls at the time point when enhanced barrier dysfunction was observed during DSS ( Figure 5d) .
Finally, expression of the mucin, Muc-2, has been demonstrated to be essential in maintaining intestinal epithelial barrier function. 29 Previous findings suggest that adenosine signaling can upregulate Muc-2 in epithelial cells. 35 We observed no appreciable difference in Muc-2 expression in Adora2b Figure S3) . Taken together, these findings suggest that the intestinal epithelial Adora2b receptor does not protect the epithelial barrier by suppressing cytokine-induced Days after DSS Colon length (cm) Figure 3 Epithelial-specific deletion of the Adora2b (A2B adenosine receptor) receptor results in significantly increased susceptibility to acute colitis. Mice with intestinal epithelial specific deletion of Adora2b (Adora2b fl/fl VillinCre þ ) were generated and exposed to water or DSS (dextran sulfate sodium, 3-3.5%) along with their wild-type Cre controls (VillinCre þ ). Mice were killed at 3, 4, and 7 days after DSS, and colons harvested by blunt dissection. (a) Daily weight measurements were assessed for each group of mice. (b) Following harvest at day 3, 4, or 7 colon lengths were measured. Results are representative of one to two independent experiments per time point with 4-18 mice per group. (c) On day 4 after DSS, FITC (fluorescein isothiocyanate)-dextran was administered by oral gavage (0.6 mg g À 1 at 80 mg ml À 1 ) 4 h before killing and serum collection. Fluorescence measurement was used to determine FITC levels; n ¼ 3-8 mice per group from one experiment. (d) Following harvest at day 7 after DSS, colon tissue was homogenized and tissue cytokines were measured by Meso Scale (Meso Scale Discovery, Rockville, MD). Results are displayed normalized to protein content and are representative of 4-6 mice per group. (e) Representative histological sections from distal colon of Adora2b fl/fl VillinCre þ or VillinCre þ mice harvested following 7 days DSS. Bar ¼ 100 mm; images are acquired at original magnification Â 10. (f) Bar graph of blinded histological scoring of the distal colon following 7 days of DSS; n ¼ 7-10 mice per group. Unless stated otherwise, results are representative of two to three independent experiments with 4-10 mice per DSS group and are displayed as mean±s.e.m. Two-way analysis of variance (ANOVA) with post hoc Bonferroni t-test was used to determine statistical weight change, but in all other cases Student's t-test was used. *Po0.05. epithelial barrier permeability, by altering MLC phosphorylation status, by altering NF-kB transcriptional activity, or by affecting either intestinal epithelial cell apoptosis or Muc-2 expression.
Adora2b regulates epithelial barrier resealing
Having observed that Adora2b signaling was not effective in altering mechanisms associated with enhanced epithelial barrier breakdown, we directed our studies to look at alternate mechanisms by which Adora2b receptor signaling could improve epithelial barrier function. To mimic our in vivo model, we genetically deleted Adora2b in T84 intestinal epithelial cells in vitro (Supplementary Figure S5b) . We used a calcium switch assay involving chelation of calcium with EDTA, which has been demonstrated to cause junction disassembly and a rapid increase in epithelial barrier permeability that is recoverable by the reintroduction of calcium. 36, 37 This allows for the assessment of epithelial junction regulation during acute disruption of the barrier such as that observed in DSS. Importantly, this assay allows us to assess the ability of the epithelial barrier to recover. Barrier recovery was monitored by measuring the rate at which a FITC-labeled dextran moved from the apical to the basolateral aspect of epithelial monolayers once calcium was reintroduced ( Figure 6) . The method by which this rate was calculated is discussed in Supplementary Materials. The rate at which control knockdown (KD) cells or vehicle-treated cells repair is defined as 1 and data are displayed as a fold change relative to this rate to account for interexperiment variability. Adora2b KD cells demonstrated a significantly slower recovery of barrier function compared with their control KD cells (Figure 6a) . A previous study implicated the phosphorylation of the focal adhesion protein VASP at Ser 157 in cAMP-induced epithelial barrier repair following acute disruption. 37 One of the major intracellular pathways downstream of the Adora2b receptor is the cAMP-protein Figure 4 Treatment with an Adora2b (A2B adenosine receptor) agonist mediates mucosal protection observed in a model of acute colitis. Gender-, age-, and weight-matched C57BL/6 mice were treated with an Adora2b-specific agonist (BAY 60-6583; 1.2-1.25 mg kg À 1 per day) or vehicle (30% Solutol HS15 in 0.9% saline) using a subcutaneous osmotic pump beginning 1 day before administration of DSS (dextran sulfate sodium, 3.5-4%) for 6 days. Mice exposed to DSS were orally gavaged with FITC (fluorescein isothiocyanate)-dextran (0.6 mg g À 1 at 80 mg ml and are representative of one to two independent experiments with 3-7 mice per group. Two-way analysis of variance (ANOVA) with post hoc Bonferroni t-test was used to determine statistical weight change, but in all other cases Student's t-test was used. *Po0.5; **Po0.001.
Adora2b agonist DSS colon
kinase A (PKA) pathway. 3 We have demonstrated that Adora2b signaling rapidly enhances cAMP levels in T84 intestinal epithelial cells (within 30 min: Supplementary Figure S4c) . Within 60 min of calcium reintroduction the epithelial barrier rapidly recovers. 37 In this instance, a marked increase in VASP phosphorylation at Ser 157 was observed by 60 min, which diminished thereafter. 37 We monitored protein levels of p-VASP (Ser ) and total VASP levels were determined by Western blot analysis. Results are representative of three independent experiments with 2 wells per time point per experiment. (c) T84 intestinal epithelial cells were used in calcium switch assays. Vehicle or the Adora2b-specific agonist (BAY 60-6583; 10 mM) was added to both the basolateral and apical aspects of the cells at the beginning of the recovery period. Barrier restitution rate was determined as described in a. Results are representative of three independent experiments with 4-6 wells per experiment. (d) T84 intestinal epithelial cells were treated as described in c and cells were harvested at different time points during the recovery period as indicated. Total protein was extracted and p-VASP (Ser 157 ) and total VASP levels were determined by Western blot analysis. Results are representative of three independent experiments with 2 wells per time point per experiment. (e) Calcium switch assays were performed with T84 cells as described in c. Cells were allowed to recover for 30 min in the presence of vehicle or Adora2b agonist before fixation with 2% paraformaldehyde. Cells were costained with a p-VASP (Ser during the first 60 min of barrier recovery, as observed previously (Figure 6b) . 37 Importantly, Adora2b KD cells were unable to phosphorylate VASP (Ser 157 ) to the same level as their control cells at time points analyzed and did not exhibit any alteration in the timecourse of VASP (Ser 157 ) phosphorylation. In contrast, T84 wild-type cells treated from the onset of recovery with an Adora2b-specific agonist (BAY 60-6583; 10 mM) exhibited an almost 40% increase in the rate of barrier recovery compared with vehicle-treated controls (Figure 6c ). We noted a very rapid and sustained elevation of p-VASP (Ser 157 ) in agonist-treated cells over that in vehicle-treated controls during barrier recovery (Figure 6d) . The position at which VASP is detected by Western blot makes loading quantification hard to determine. Therefore, our Western blot data demonstrate a qualitative trend in alteration of VASP phosphorylation as a consequence of Adora2b signaling. Agonist specificity for Adora2b-induced VASP (Ser 157 ) phosphorylation was confirmed by pretreatment of T84 cells with a specific Adora2b antagonist before agonist cotreatment. Under these conditions, the Adora2b agonist failed to phosphorylate VASP (Ser 157 ) (Supplementary Figure S6) . Finally, we confirmed our Western blot findings by immunofluorescence staining (Figure 6e ). We observed a substantial portion of p-VASP (Ser 157 ) localizing to E-cadherin-positive T84 epithelial cell junctions within 30 min of Adora2b agonist treatment during barrier recovery compared with vehicle controls (Figure 6e ). This is consistent with a more rapid rate of barrier recovery in agonist-treated cells (Figure 6c) . These results outline a direct effect of Adora2b signaling on epithelial barrier function, which our results suggest is mediated through the phosphorylation of VASP (Ser 157 ).
PKA activity mediates Adora2b-driven VASP (Ser 157 ) phosphorylation PKA has been directly implicated in epithelial barrier recovery and VASP (Ser 157 ) phosphorylation. 37 PKA is a known downstream mediator of Adora2b signaling. 3 Treating T84 cells with the PKA inhibitor (H89; 30 mM) before administration of the Adora2b-specific agonist (BAY 60-6583; 1 and 10 mM) revealed a concentration-dependent increase in p-VASP (Ser 157 ) that was significantly attenuated by the inhibition of PKA (Figure 7a) . Analyzing the Adora2b signaling pathway during barrier recovery revealed a profound effect of PKA inhibition on the ability of the Adora2b agonist to phosphorylate VASP (Ser 157 ) (Figure 7b) . We conclude that Adora2b signaling through PKA plays a significant role in VASP (Ser 157 ) phosphorylation during barrier recovery. ) and total VASP levels were determined by Western blot analysis. (b) Calcium switch assays were performed using T84 intestinal epithelial cells with a fully competent barrier. Cells were placed in calcium-depleting conditions until barrier function was fully compromised and subsequently allowed to recover in calcium complete media for the time points outlined. Cells were treated on both the basolateral and apical aspect with the Adora2b-specific agonist (BAY 60-6583; 10 mM) in the presence or absence of the PKA inhibitor (H89, 30 mM) from the beginning of the recovery period for the time points indicated. Cells were harvested, total protein extracted, and p-VASP (Ser 157 ) and total VASP levels were determined by Western blot analysis. Results are representative of three independent experiments with 2-3 wells per time point per experiment. ) costaining of E-cadherin-positive cells was calculated using Olympus software (Shinjuku, Tokyo, Japan). Image analysis was performed in a blinded manner using images acquired at the same settings, with a defined threshold of intensity applied to all images. Results represent the percentage staining of three identically sized randomly selected E-cadherin-positive regions of interest from each image. Day 4 results represent one image per mouse with four mice in each group. Day 7 results represent 4-5 images per mouse with 5-7 mice per group. Data are displayed as the mean ± s.e.m. Statistical analysis was performed using the Student's t-test. *Po0.05 and ***Po0.0001. epithelial barrier (Figure 6c, d) . We therefore analyzed p-VASP (Ser 157 ) expression in vivo following Adora2b agonist treatment during DSS (Figure 9 ). Immunofluorescence analysis was performed in colonic tissue following vehicle or Adora2b agonist administration for 6 days during DSS, as discussed above (Figure 4) . Adora2b agonist-treated mice exhibited a significantly higher level of p-VASP (Ser 157 ) expression in E-cadherin-positive cells in comparison with vehicle-treated mice (Figure 9a) . A large portion of epithelial p-VASP (Ser 157 ) was observed to localize to E-cadherin-positive epithelial cell junctions following Adora2b agonist treatment (Figure 9a) . p-VASP (Ser 157 ) levels in the epithelium were quantified by measuring the percentage of staining in standardized sections of E-cadherin-positive tissue (Figure 9b) . These findings indicate that an Adora2b agonist can induce epithelial VASP (Ser 157 ) phosphorylation to facilitate a barrier-protective response in DSS colitis.
DISCUSSION
Current studies point to the key role played by dysregulated mucosal homeostasis in the development of IBD. 1 As such, better understanding of mucosal responses in the context of IBD is of great relevance to the identification of novel therapeutic options.
The release of adenosine from inflamed tissues and its receptor signaling pathways have been highlighted as an endogenous mechanism to dampen inflammation. 3 In the context of IBD, maintaining high tissue levels of adenosine has been demonstrated to protect the intestinal mucosa. [14] [15] [16] However, the predominant adenosine receptor signaling pathway that mediates protection during IBD remains to be elucidated. There is evidence that adenosine signaling through the Adora2a receptor is protective in a T-cell-mediated murine model of IBD. 17, 38 However, an Adora2a agonist was ineffective in an acute colitis model, indicating a potential tissue-and Figure 9 Adora2b (A2B adenosine receptor) agonist treatment results in significantly increased localization of p-VASP (phosphorylated vasodilatorstimulated phosphoprotein) (Ser 157 ) to the intestinal epithelial barrier in vivo during DSS (dextran sulfate sodium) colitis. Gender-, age-, and weightmatched C57BL/6 mice were treated with an Adora2b-specific agonist (BAY 60-6583; 1.2-1.25 mg/kg À 1 per day) or vehicle for 6 days during DSS as described in Figure 4 . Colons were harvested by blunt dissection and formalin fixed. (a) Formalin-fixed colons were deparaffinized and rehydrated. Sections were costained with p-VASP (Ser 157 ) and E-cadherin antibodies as described in Figure 7a and b. Representative images were acquired at original magnification Â 20. Bar ¼ 50 mm. (b) p-VASP (Ser 157 ) staining of E-cadherin-positive cells was calculated as described in Figure 7c . Results are representative of 1-3 images per mouse with 5-7 mice per group. Statistical analysis was performed using the Student's t-test. Data are displayed as the mean±s.e.m. ***Po0.0001.
context-specific role for adenosine signaling in the inflamed intestine. 39 This is further highlighted when considering the potential role of the Adora2b adenosine receptor in IBD. To date, studies have indicated both a protective 12, 18 and deleterious effect [19] [20] [21] of Adora2b receptor signaling at the level of the intestinal epithelium in murine models of colitis. Divergent results observed may be because of specific effects of Adora2b signaling at alternative stromal tissue sites. Indeed vascular endothelial expression of the Adora2b receptor has been demonstrated to be an important protective pathway in another model of acute mucosal inflammation. 8 Therefore, we were interested in defining the Adora2b signaling events occurring on stromal tissue during acute intestinal inflammation. We postulated that the Adora2b receptor had a tissuespecific role to play during the development of IBD.
To dissect the role of Adora2b on stromal tissue during acute colitis, we examined mice lacking the Adora2b receptor (Adora2b À / À ) over a time course of DSS ( Figure 1) . We observed significant increases in disease activity parameters early in the time course of disease in Adora2b À / À mice compared with wild-type controls ( Figure 1) . As early as day 3, Adora2b À / À mice exhibited pronounced colonic shortening and loss of epithelial barrier function (Figure 1b, c,  respectively) . This culminated in considerably greater histological disease (Figure 1e-f ) and robust recruitment of neutrophils to the colonic lamina propria of Adora2b À / À mice in comparison with wild-type controls (Figure 1d) . Taken together, our findings suggest a protective role for Adora2b signaling during acute intestinal inflammation.
Previous findings in a model of hypoxia-driven inflammation indicate that Adora2b receptors on the vascular endothelium mediate a protective response in acute inflammation. 8 Using a novel Adora2b-flox mouse line, we generated mice with tissue-specific deletion of Adora2b on the vascular endothelium. These mice did not exhibit any alteration in disease outcome compared with their genetic controls during DSS colitis (Figure 2 ), prompting us to consider an alternative stromal source of Adora2b-mediated mucosal protection.
Intestinal epithelial cells express a high level of the Adora2b receptor, which can be upregulated by mediators associated with colitis. 22 Using a tissue-specific gene approach, we demonstrated that genetic loss of Adora2b in intestinal epithelial cells led to significantly greater disease activity during DSS ( Figure 3) . As in whole-body Adora2b deletion (Figure 1) , we observed pronounced early onset of disease in mice lacking epithelial Adora2b (Adora2b fl/fl VillinCre) culminating in worsened DSS colitis outcome in Adora2b fl/fl VillinCre mice in all parameters measured (Figure 3 ).
Given our current findings, we hypothesized that pharmacologic targeting of the Adora2b receptor may be of therapeutic benefit in acute colitis. Mice administered an Adora2b-specific agonist were profoundly protected from development of DSS colitis (Figure 4) . Importantly, Adora2b agonist treatment improved intestinal epithelial barrier function (Figure 4c) , suggesting agonist-directed mucosal protection in acute colitis. While previous studies illustrated that an Adora2b antagonist is deleterious in colitis, 12 this is the first study demonstrating that Adora2b signaling can be therapeutically targeted for tissue protection in a model of IBD.
Our observations to date suggest that endogenous epithelial Adora2b is a barrier-protective signaling pathway in acute colitis. We therefore concentrated our efforts on elucidating the functional role of the Adora2b receptor on the intestinal epithelium during the acute response in DSS. Generally, DSS colitis is characterized by elevated tissue cytokine levels, enhanced epithelial cell apoptosis, and loss of intestinal barrier function. 28, 40, 41 We pursued studies to interrogate the role of the Adora2b receptor in processes known to be involved in these features of early mucosal barrier dysfunction. Previous study suggests that Adora2b signaling induces the release of the proinflammatory cytokine, IL-6, 42 and the anti-inflammatory cytokine, IL-10, 12 from the intestinal epithelium. Adora2b fl/fl VillinCre mice were observed to have a slightly elevated tissue content of IL-6 but no significant alteration in IL-10 compared with control mice (Figure 3d ). In contrast, Adora2b agonisttreated mice exhibited a significant decrease in IL-6 tissue levels and a reduction in IL-10 compared with vehicle controls (Figure 4d ). Taking these findings in the context of the previous studies mentioned, our results suggest that direct regulation of cytokine release at the epithelium was not the predominant function of the epithelial Adora2b receptor in our model. We next investigated the potential role of Adora2b receptor signaling in mechanisms that promote epithelial barrier breakdown during DSS colitis. However, we failed to observe an effect of Adora2b signaling on cytokine-induced epithelial barrier permeability, MLC phosphorylation, NF-kB transcriptional activation, epithelial cell apoptosis (Figure 5a-d, respectively) , or mucin-2 expression (Supplementary Figure S3 ). These studies were predominantly performed in vitro and were used to direct additional in vitro and in vivo studies. We cannot abandon the possibility that one of the mechanisms excluded by our in vitro studies may contribute to the phenotype we observe in our animal model. Having ruled out direct effects of epithelial Adora2b receptor signaling on epithelial cytokine release and processes implicated in epithelial barrier breakdown, we considered a potential role for the Adora2b in mechanisms involved in epithelial barrier repair. To do this, we used an in vitro model with polarized intestinal epithelial cells. First, we confirmed the capability of the Adora2b-specific agonist to induce known receptor second messenger pathways and demonstrated efficient increase in intracellular cAMP following agonist treatment (Supplementary Figure S4) . We subsequently generated genetic knockout of Adora2b in intestinal epithelial cells to mirror our in vivo model (Supplementary Figure S5b) . To model epithelial tight junction rearrangement and barrier dysfunction observed in IBD, we used a calcium switch assay in vitro. 36, 37 Importantly, in this model epithelial junction reassembly and repair can be studied. Adora2b KD cells exhibited impaired recovery of barrier function following junction disassembly (Figure 6a) , whereas agonist treatment during recovery significantly enhanced the rate of barrier restitution when compared with vehicle treatment (Figure 6c ). Considering our observations that Adora2b signaling was capable of enhancing barrier recovery ( Figure 6 ) and also elevated intracellular cAMP (Supplementary Figure S4) , we noted that cAMP-mediated phosphorylation of VASP had previously been implicated in recovery of epithelial barrier function. 37 In this study, expression of VASP in the intestinal epithelium was demonstrated to be necessary for the recovery of epithelial barrier function, with phosphorylated VASP (p-VASP Ser 157 ) localizing to the junction during barrier recovery. Using these previous findings, we examined our (Figure 3c) . In contrast, mice treated with the Adora2b agonist during DSS were observed to have a pronounced increase in p-VASP (Ser 157 ) at epithelial cell junctions compared with vehicle-treated controls ( Figure 9 ). This matched with our finding of significantly reduced epithelial barrier permeability in agonist-treated mice compared with vehicle controls at the same time point (Figure 4c ). These observations suggest that Adora2b signaling in the intestinal epithelium in vivo regulates VASP (Ser 157 ) phosphorylation to enhance epithelial barrier function during acute inflammation. Of note, we did not analyze the expression of other junctional proteins in these mice and therefore cannot exclude the possibility that in vivo Adora2b signaling may have additional effects on epithelial junction proteins.
In this study, we used a whole-body and tissue-specific genetic approach to define the contribution of Adora2b to mucosal inflammation. Initial studies in mice with whole-body deletion of Adora2b (Adora2b À / À ) demonstrated rapid, early onset of mucosal inflammation in Adora2b À / À mice during experimental colitis. Excitingly, we determined that intestinal epithelial-specific Adora2b signaling is a key pathway in mediating mucosal barrier protection during acute colitis. In vitro and in vivo analysis points to Adora2b phosphorylation of VASP (Ser 157 ) and its localization to epithelial cell junctions as a potential mechanism by which endogenous Adora2b mediates a barrier protective effect. Herein, we present novel studies demonstrating for the first time that Adora2b signaling can be exploited as a therapeutic pathway in a model of IBD. Taken together, we have defined that specific signaling through intestinal-epithelial Adora2b receptors provides potent protection during acute intestinal inflammation, an important finding that may be exploited as a novel therapeutic strategy in IBD.
METHODS DSS colitis. Adora2b-deficient mice, 8 mice with tissue-specific Adora2b deletion (for more details see Supplementary Materials), matched genetic controls, or C57BL/6 mice were used in DSS studies (3-4.5%), as described previously. 13, 44, 45 Adora2b agonist (BAY 60-6583; Tocris Bioscience, Bristol, UK) or vehicle (30% SolutolHS15 in 0.9% saline; BASF, Florham Park, NJ) was administered by subcutaneous osmotic pump (Alzet; DURECT Corporation, Cupertino, CA) at 1.2-1.25 mg kg À 1 mouse per day.
Flow cytometric analysis. Flow cytometric analysis of lamina propria leukocytes was performed with antibodies against GR-1 (RB6-8C5), SiglecF (E50-2440), F4/80 (BM8), CD11c (N418), MHCII (M5/ 114.15.2), and CD45 (30-F11), as outlined previously.
13,43
In vivo permeability. Tissue permeability was measured using FITC-labeled dextran as described previously.
13
Cell culture and generation of short hairpin RNA KD. Cells were cultured as outlined in Supplementary Materials. 30,46-48 Constitutive KD of Adora2b was generated using MISSION shRNA technology (as described in Supplementary Materials).
In vitro FITC-dextran flux assay. FITC-dextran (3 kDa) flux assays were performed in T84 intestinal epithelial cells following cytomix treatment (TNFa, IL-1b, and IFNg; 10ng/ml) in the presence of vehicle or Adora2b agonist (BAY 60-6583, 10 mM) as described 13, 49 (for more details see Supplementary Materials).
Luciferase reporter assay. Caco-2 intestinal epithelial cells were transfected with equal amounts of NF-kB luciferase and Renilla luciferase plasmids. Following 24 h, cells were treated with vehicle, TNFa (10 ng/ml), the Adora2b agonist alone (BAY 60-6583, 10 mM), or in combination with TNFa. Luminescence was detected as described in Supplementary Materials. TUNEL staining. Apoptotic epithelial cells were detected by TUNEL staining of formalin-fixed, paraffin-embedded tissue (for details see Supplementary Materials).
Calcium switch assay. Calcium switch assays in T84 intestinal epithelial cells were performed as outlined previously. 36 Barrier restitution rate was determined by the addition of FITC-dextran (10 kDa) to the apical aspect at the time of recovery and sampling of FITC in the basolateral compartment (for further details see Supplementary Methods).
Western blot analysis. Equal amounts of whole-cell lysates were separated by gel electrophoresis, transferred, and membranes incubated with either anti-human p-VASP (Ser 157 ) (Cell Signaling, Danvers, MA), anti-human anti-VASP (BD Transduction Laboratories, San Jose, CA), anti-human p-MLC-2 (Ser 19 ) (Cell Signaling), anti-human MLC-2 (Cell signaling), or anti-actin (Calbiochem).
Immunofluorescence. Paraffin-embedded sections or paraformaldehyde fixed cell membranes were incubated with anti-human p-VASP (Ser 157 ) or anti-human E-cadherin followed by fluorescent detection.
Statistical analysis. GraphPad Prism Analysis software (GraphPad Software, La Jolla, CA) was used to perform statistical analysis. Analysis of variance (ANOVA) followed by post-test or Student's t-test was used where appropriate and results are expressed as mean ± s.e.m.
For further details see Supplementary Materials.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
